



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/821,604	04/08/2004	Michel Gilbert	019633-000129US	1518

20350	7590	07/16/2007
TOWNSEND AND TOWNSEND AND CREW, LLP		
TWO EMBARCADERO CENTER		
EIGHTH FLOOR		
SAN FRANCISCO, CA 94111-3834		

EXAMINER	
SWOPE, SHERIDAN	

ART UNIT	PAPER NUMBER
1652	

MAIL DATE	DELIVERY MODE
07/16/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.



UNITED STATES DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
10821604	4/8/2004	GILBERT ET AL.	019633-000129US

TOWNSEND AND TOWNSEND AND CREW, LLP
TWO EMBARCADERO CENTER
EIGHTH FLOOR
SAN FRANCISCO, CA 94111-3834

EXAMINER

Sheridan L.. Swope

ART UNIT	PAPER
1652	20070627

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner for Patents


The amendment filed April 26, 2007 is non-responsive for the following reasons.

A restriction/election requirement for this case was mailed July 13, 2006, wherein the claims were restricted into four inventions:

- I. Claims 43 and 51, in part, 44 and 46, drawn to a polypeptide having a-2,3-sialytransferase activity.
- II. Claims 43 and 51, in part, 45, drawn to a polypeptide having a-2,3-sialytransferase and a-2,8-sialytransferase activities.
- III. Claims 43 and 51, in part, 47 and 48; drawn to a polypeptide having b-1,3-galactosyltransferase activity.
- IV. Claims 43 and 51, in part, 49 50, drawn to a polypeptide having b-1,4-N-acetylglucosaminyl transferase activity.

It is noted that none of the restricted claims were directed to a polypeptide having b-1,4-N-acetylglucosaminyl transferase activity

On October 27, 2006, Applicants elected Invention IV. A First Action on the Merits examining the elected invention, drawn to a polypeptide having b-1,4-N-acetylglucosaminyl transferase activity, was mailed October 27, 2006. On April 26, 2007 Applicants filed a response comprising claims amended to recite a polypeptide having b-1,4-N-acetylglucosaminyl transferase activity; said amended claims are not directed to the elected invention. Thus, the amendment filed April 26, 2007 is non-responsive.


SHERIDAN SWOPE, PH.D.
PRIMARY EXAMINER